Close Menu

NEW YORK (360Dx) – Deep Lens said today that it has closed a $14 million Series A round to further expand its artificial intelligence and platform product development activities. It will also use the financing to scale its service, sales, and marketing organizations to support demand and growth for its approach to clinical trial recruitment.

The Series A closing comes three months after Columbus, Ohio-based Deep Lens completed a venture capital-led seed equity round, bringing its funding to date to $17.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.